Amneal Pharmaceuticals (AMRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 93-4225266 (State or other jurisdict ...

Have you been paying attention to shares of Amneal Pharmaceuticals (AMRX) ? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $9.32 in the previous session. Amneal Pharmaceuticals has gained 51.6% since the start of the year compared to the 4.7% move for the Zacks Medical sector and the 0.5% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Balaji Prasad - Barclays Bank Leszek Sulewski - Tr ...

Amneal Pharmaceuticals (AMRX) reported $702.47 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 13.3%. EPS of $0.16 for the same period compares to $0.19 a year ago. The reported revenue represents a surprise of +1.27% over the Zacks Consensus Estimate of $693.68 million. With the consensus EPS estimate being $0.13, the EPS surprise was +23.08%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.14 per share when it actually produced earnings of $0.16, delivering a surprise of 14.29%. Over the last fou ...

Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS ‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Af irms 2024 Full Year Guidance ‒ BRIDGEWATER, NJ, November 8, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2024. "Q3 was an excellent quarter where we continued to drive ...

Wall Street analysts expect Amneal Pharmaceuticals (AMRX) to post quarterly earnings of $0.13 per share in its upcoming report, which indicates a year-over-year decline of 31.6%. Revenues are expected to be $693.68 million, up 11.9% from the year-ago quarter.The current level reflects a downward revision of 3.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Be ...

Efficiency level measures a company's capability to transform available input into output and is often considered an important parameter for gauging its potential to make profits. A company with a high-efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance. However, at times, it becomes difficult to measure the efficiency level of a company. This is why one must consider the popular efficiency ratios listed below while selecting stocks. T ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Amneal Pharmaceuticals (AMRX) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 8, 2024, might help the stock move higher if these key numbers are ...